Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 4/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20370501 | 0.97 | RAB9A (0.41) | RAB9ARARBCYP2C9GPR119S1PR3 | |
| SCHEMBL19855875 | 0.97 | RAB9A (0.46) | RAB9ACYP2C9GPR119S1PR3LMNA | |
| SCHEMBL19855051 | 0.96 | RAB9A (0.45) | RAB9ACYP2C9GPR119S1PR3LMNA | |
| SCHEMBL19855991 | 0.94 | RAB9A (0.43) | RAB9ACYP2C9GPR119S1PR3LMNA | |
| SCHEMBL19855818 | 0.92 | RAB9A (0.45) | RAB9ACYP2C9GPR119S1PR3LMNA | |
| SCHEMBL19854618 | 0.91 | BTK (0.38) | RAB9AP2RY14MMP2 | |
| SCHEMBL19854024 | 0.91 | RAB9A (0.38) | RAB9AGPR119P2RY14 | |
| SCHEMBL19854626 | 0.91 | BTK (0.41) | RAB9ARARBCYP2C9P2RY14 | |
| SCHEMBL19854039 | 0.90 | BTK (0.37) | RAB9AP2RY14ALDH1A1 | |
| SCHEMBL19854086 | 0.89 | BTK (0.37) | RAB9ACYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662379-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
| WO-2018025974-A1 | LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE | JNC株式会社 | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, MBD2, PAXBP1 | RAB9A 4014/4885RARB 1437/4885CYP2C9 3761/4885 |
| US-10662379-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | SP1, MBD2, PAXBP1 | RAB9A 4014/4885RARB 1437/4885CYP2C9 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.